LatentSpace is an AI-driven virtual drug company that utilizes variational autoencoders for in-silico testing of drug efficacy, toxicity, and retrosynthesis. The platform accelerates the identification of safe and effective therapeutic candidates for challenging cancers and complex diseases, significantly reducing the time and cost of traditional drug development.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery is a lengthy and expensive process, often taking many years and requiring significant resources to identify and validate promising therapeutic candidates. The high failure rate of drug candidates in clinical trials further exacerbates the challenges of developing effective treatments for complex diseases.
Solution
LatentSpace is an AI-driven drug discovery company that leverages variational autoencoders (VAEs) to accelerate the identification of safe and effective therapeutic candidates. The platform conducts comprehensive in-silico testing of drug efficacy, toxicity, and retrosynthesis, enabling the rapid evaluation of novel compounds. By prioritizing drug design based on efficacy and safety before identifying specific targets, LatentSpace significantly reduces the time and cost associated with traditional drug development. The company's technology integrates sophisticated predictors with VAEs to generate novel therapies for challenging cancers and complex diseases.
Target Audience
LatentSpace's primary customers are pharmaceutical companies and research institutions seeking to accelerate drug discovery and reduce development costs for treatments targeting challenging cancers and complex diseases.
Features
- AI-driven platform utilizing variational autoencoders (VAEs) for drug discovery
- In-silico testing for drug efficacy, toxicity, and retrosynthesis
- Prioritization of drug design based on efficacy and safety
- Integration of sophisticated predictors with VAEs
- Generation of novel therapeutic candidates